CD-19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell therapy

Bookmark and Share
Published: 20 Jun 2019
Views: 824
Rating:
Save
Dr Michaela Kotrova - Universitätsklinikum Schleswig-Holstein, Kiel, Germany

Dr Michaela Kotrova speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting the poster she was presenting on acute lymphoblastic leukaemia patients who were treated with CD19-directed immunotherapies.

She explains that by identifying somatic mutations acquired at the time of CD19-negative relapse in patients after blinatumomab treatment, they found CD19 mutation frequency after blinatumomab treatment is lower than after CAR T-cell treatment.

Dr Kotrova explains the next steps to investigating this finding further and the importance of understanding the mechanism of CD-19 loss.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.